Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use.

Schizophrenia Bulletin
Ana González-PintoCelso Arango

Abstract

To examine the influence of cannabis use on long-term outcome in patients with a first psychotic episode, comparing patients who have never used cannabis with (a) those who used cannabis before the first episode but stopped using it during follow-up and (b) those who used cannabis both before the first episode and during follow-up. Patients were studied following their first admission for psychosis. They were interviewed at years 1, 3, and 5. At follow-up after 8 years, functional outcome and alcohol and drug abuse were recorded. Patients were classified according to cannabis use: 25 had cannabis use before their first psychotic episode and continuous use during follow-up (CU), 27 had cannabis use before their first episode but stopped its use during follow-up (CUS), and 40 never used cannabis (NU). The 3 groups did not differ significantly in symptoms or functional outcome at baseline or during short-term follow-up. The CUS group exhibited better long-term functional outcome compared with the other 2 groups and had fewer negative symptoms than the CU group, after adjusting for potential confounders. For the CUS group, the effect size was 1.26 (95% confidence interval [CI]=0.65 to 1.86) for functional outcome and -0.72 (95% CI=...Continue Reading

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Feb 1, 1992·Acta Psychiatrica Scandinavica·V Peralta, M J Cuesta
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Apr 1, 1994·Archives of General Psychiatry·D H LinszenM E Lenior
Dec 1, 1993·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·E S Casper, J R Regan
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Mar 3, 2004·The American Journal of Psychiatry·Natalie D VeenRené S Kahn
Jun 25, 2005·Schizophrenia Bulletin·Cécile HenquetJim van Os
Jul 16, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anton GrechRobin M Murray
Nov 22, 2005·Schizophrenia Research·Darryl WadePatrick D McGorry
Aug 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·L HidesR McD Young
Jan 3, 2007·Archives of General Psychiatry·Stephen M StrakowskiJennifer Amicone
Mar 6, 2007·Schizophrenia Bulletin·Suzanne ArchieRobert B Zipursky
Mar 16, 2007·Acta Psychiatrica Scandinavica·J Addington, D Addington
Aug 9, 2007·Schizophrenia Research·Jean-Paul SeltenRené S Kahn
Feb 19, 2008·The American Journal of Psychiatry·Monica RaisRené Kahn
Aug 7, 2008·The Journal of Clinical Psychiatry·Ana González-PintoEduard Vieta
Nov 4, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Stanley ZammitGlyn Lewis
Jan 7, 2009·Archives of General Psychiatry·Paolo Fusar-PoliPhilip K McGuire
Aug 28, 2009·The Journal of Clinical Psychiatry·Mauricio TohenUNKNOWN European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Advisory Board

❮ Previous
Next ❯

Citations

Jun 13, 2013·Psychopharmacology·H BugraA Riecher-Rössler
Jul 3, 2013·Asian Journal of Psychiatry·Preeti Parakh, Debasish Basu
Sep 9, 2011·Psychological Medicine·J H MeijerUNKNOWN Genetic Risk and Outcome of Psychosis (GROUP) Investigators
Mar 15, 2015·Current Addiction Reports·Samuel T WilkinsonDeepak Cyril D'Souza
Mar 1, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Grant E SaraWayne C Hall
Jul 24, 2014·Psychological Medicine·L R ValmaggiaP K McGuire
Oct 9, 2012·Child and Adolescent Psychiatric Clinics of North America·Ann E MaloneyJean A Frazier
Sep 3, 2011·Psychiatry Research·Ana González-PintoJose de Leon
Oct 1, 2013·European Psychiatry : the Journal of the Association of European Psychiatrists·M ArrasateA González-Pinto
Sep 2, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·C González-BlanchM Alvarez-Jimenez
Jul 23, 2011·Schizophrenia Research·Clifford M CassidyAshok K Malla
Feb 6, 2015·Psychological Medicine·F J van der MeerUNKNOWN Genetic Risk and Outcome of Psychosis (GROUP) Investigators
Mar 23, 2013·Schizophrenia Research·Albert BatallaMiguel Bernardo
Aug 12, 2016·PloS One·Ana González-PintoUNKNOWN PEPs Group
Sep 7, 2016·Early Intervention in Psychiatry·Kellie L HaddenBarbara Thomas
Dec 22, 2016·Journal of Child and Adolescent Mental Health·Deirdre PieterseWendy Vogel
Aug 20, 2015·The Australian and New Zealand Journal of Psychiatry·Hannah MylesMatthew Large
Mar 5, 2014·The Australian and New Zealand Journal of Psychiatry·Matthew LargeOlav Nielssen
Mar 1, 2012·The Australian and New Zealand Journal of Psychiatry·Katherine MullinMatthew Large
May 14, 2014·The Australian and New Zealand Journal of Psychiatry·Grant E SaraWayne C Hall
Jan 24, 2013·The Australian and New Zealand Journal of Psychiatry·Pal GuptaMatthew Large
Aug 6, 2019·Acta Psychiatrica Scandinavica·E Setién-SueroR Ayesa-Arriola
Feb 16, 2017·Schizophrenia Bulletin·Melissa A WeibellSvein Friis
Jul 30, 2019·Frontiers in Psychiatry·Melissa A WeibellWenche Ten Velden Hegelstad
Nov 21, 2019·The South African Journal of Psychiatry : SAJP : the Journal of the Society of Psychiatrists of South Africa·Yanga ThunganaStephan van Wyk

❮ Previous
Next ❯

Software Mentioned

R

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.